1
|
Driban JB, Harkey MS, Barbe MF, Ward RJ, MacKay JW, Davis JE, Lu B, Price LL, Eaton CB, Lo GH and McAlindon TE: Risk factors and the natural history of accelerated knee osteoarthritis: A narrative review. Bmc Musculoskel Dis. 21:3322020. View Article : Google Scholar
|
2
|
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet. 392:1789–1858. 2018. View Article : Google Scholar
|
3
|
Bruyère O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, Berenbaum F, Dennison E, Devogelaer JP, Hochberg M, et al: Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drug Aging. 32:179–187. 2015. View Article : Google Scholar
|
4
|
Goldring SR and Goldring MB: Changes in the osteochondral unit during osteoarthritis: Tructure, function and cartilage-bone crosstalk. Nat Rev Rheumatol. 12:632–644. 2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Zhu X, Chan YT, Yung PSH, Tuan RS and Jiang Y: Subchondral bone remodeling: A therapeutic target for osteoarthritis. Front Cell Dev Biol. 8:6077642021. View Article : Google Scholar : PubMed/NCBI
|
6
|
Li G, Ma Y, Cheng TS, Landao-Bassonga E, Qin A, Pavlos NJ, Zhang C, Zheng Q and Zheng MH: Identical subchondral bone microarchitecture pattern with increased bone resorption in rheumatoid arthritis as compared to osteoarthritis. Osteoarthr Cartilage. 22:2083–2092. 2014. View Article : Google Scholar
|
7
|
Lin C, Liu L, Zeng C, Cui ZK, Chen Y, Lai P, Wang H, Shao Y, Zhang H, Zhang R, et al: Activation of mTORC1 in subchondral bone preosteoblasts promotes osteoarthritis by stimulating bone sclerosis and secretion of CXCL12. Bone Res. 7:52019. View Article : Google Scholar : PubMed/NCBI
|
8
|
Cui Z, Xu C, Li X, Song J and Yu B: Treatment with recombinant lubricin attenuates osteoarthritis by positive feedback loop between articular cartilage and subchondral bone in ovariectomized rats. Bone. 74:37–47. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Khorasani MS, Diko S, Hsia AW, Anderson MJ, Genetos DC, Haudenschild DR and Christiansen BA: Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice. Arthritis Res Ther. 17:302015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Pereira M, Petretto E, Gordon S, Bassett J, Williams GR and Behmoaras J: Common signalling pathways in macrophage and osteoclast multinucleation. J Cell Sci. 131:jcs2162672018. View Article : Google Scholar : PubMed/NCBI
|
11
|
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:315–323. 1999. View Article : Google Scholar : PubMed/NCBI
|
13
|
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:3597–3602. 1998. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yang X, Liang J, Wang Z, Su Y, Zhou B, Wu Z, Li J, Li X, Chen R, Zhao J, et al: Sesamolin protects mice from ovariectomized bone loss by inhibiting osteoclastogenesis and RANKL-mediated NF-κB and MAPK signaling pathways. Front Pharmacol. 12:6646972021. View Article : Google Scholar
|
15
|
Zou W and Teitelbaum SL: Integrins, growth factors, and the osteoclast cytoskeleton. Ann Ny Acad Sci. 1192:27–31. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Lian WS, Ko JY, Chen YS, Ke HJ, Hsieh CK, Kuo CW, Wang SY, Huang BW, Tseng JG and Wang FS: MicroRNA-29a represses osteoclast formation and protects against osteoporosis by regulating PCAF-mediated RANKL and CXCL12. Cell Death Dis. 10:7052019. View Article : Google Scholar : PubMed/NCBI
|
17
|
Wang X, Yamauchi K and Mitsunaga T: A review on osteoclast diseases and osteoclastogenesis inhibitors recently developed from natural resources. Fitoterapia. 142:1044822020. View Article : Google Scholar : PubMed/NCBI
|
18
|
Tu Y: The development of new antimalarial drugs: Qinghaosu and dihydro-qinghaosu. Chin Med J (Engl). 112:976–977. 1999.
|
19
|
Wartenberg M, Wolf S, Budde P, Grünheck F, Acker H, Hescheler J, Wartenberg G and Sauer H: The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Lab Invest. 83:1647–1655. 2003. View Article : Google Scholar : PubMed/NCBI
|
20
|
Hwang YP, Yun HJ, Kim HG, Han EH, Lee GW and Jeong HG: Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms. Biochem Pharmacol. 79:1714–1726. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP and Ding J: Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther. 7:1017–1023. 2008. View Article : Google Scholar : PubMed/NCBI
|
22
|
Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, Yang X, Lian F and Sun L: Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford). 46:920–926. 2007. View Article : Google Scholar
|
23
|
Dong YJ, Li WD and Tu YY: Effect of dihydro-qinghaosu on auto-antibody production, TNF alpha secretion and pathologic change of lupus nephritis in BXSB mice. Zhongguo Zhong Xi Yi Jie He Za Zhi. 23:676–679. 2003.In Chinese. PubMed/NCBI
|
24
|
Feng MX, Hong JX, Wang Q, Fan YY, Yuan CT, Lei XH, Zhu M, Qin A, Chen HX and Hong D: Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts. Sci Rep. 6:190742016. View Article : Google Scholar : PubMed/NCBI
|
25
|
Li WD, Dong YJ, Tu YY and Lin ZB: Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation. Int Immunopharmacol. 6:1243–1250. 2006. View Article : Google Scholar : PubMed/NCBI
|
26
|
Zhou L, Liu Q, Yang M, Wang T, Yao J, Cheng J, Yuan J, Lin X, Zhao J, Tickner J and Xu J: Dihydroartemisinin, an anti-malaria drug, suppresses estrogen deficiency-induced osteoporosis, osteoclast formation, and RANKL-induced signaling pathways. J Bone Miner Res. 31:964–974. 2016. View Article : Google Scholar
|
27
|
Hu JP, Nishishita K, Sakai E, Yoshida H, Kato Y, Tsukuba T and Okamoto K: Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways. Eur J Pharmacol. 580:70–79. 2008. View Article : Google Scholar
|
28
|
Ryoo GH, Moon YJ, Choi S, Bae EJ, Ryu JH and Park BH: Tussilagone promotes osteoclast apoptosis and prevents estrogen deficiency-induced osteoporosis in mice. Biochem Biophys Res Commun. 531:508–514. 2020. View Article : Google Scholar : PubMed/NCBI
|
29
|
Würger T, Roschger P, Zwettler E, Fratzl P, Rogers MJ, Klaushofer K and Rumpler M: Osteoclasts on bone and dentin in vitro: Mechanism of degradation and comparison of resorption behaviour. Bone. 51:S92012. View Article : Google Scholar
|
30
|
Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH and Xu J: 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. J Bone Miner Res. 18:2159–2168. 2003. View Article : Google Scholar : PubMed/NCBI
|
31
|
Kwak SC, Cheon YH, Lee CH, Jun HY, Yoon KH, Lee MS and Kim JY: Grape seed proanthocyanidin extract prevents bone loss via regulation of osteoclast differentiation, apoptosis, and proliferation. Nutrients. 12:31642020. View Article : Google Scholar :
|
32
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
33
|
Glasson SS, Blanchet TJ and Morris EA: The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthr Cartilage. 15:1061–1069. 2007. View Article : Google Scholar
|
34
|
Zhao YG, Wang Y, Guo Z, Gu AD, Dan HC, Baldwin AS, Hao W and Wan YY: Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. J Immunol. 189:4417–4425. 2012. View Article : Google Scholar : PubMed/NCBI
|
35
|
National Research Council (US) Committee for the Update of the Guide for the Care and use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press (US); Washington, DC: 2011
|
36
|
Bei M, Tian F, Liu N, Zheng Z, Cao X, Zhang H, Wang Y, Xiao Y, Dai M and Zhang L: A novel rat model of patellofemoral osteoarthritis due to patella baja, or low-lying patella. Med Sci Monit. 25:2702–2717. 2019. View Article : Google Scholar : PubMed/NCBI
|
37
|
Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, Askin FB, Frassica FJ, Chang W, Yao J, et al: Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 19:704–712. 2013. View Article : Google Scholar : PubMed/NCBI
|
38
|
Moskowitz RW: Osteoarthritis cartilage histopathology: Grading and staging. Osteoarthr Cartilage. 14:1–2. 2006. View Article : Google Scholar
|
39
|
Zhu S, Zhu J, Zhen G, Hu Y, An S, Li Y, Zheng Q, Chen Z, Yang Y, Wan M, et al: Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J Clin Invest. 129:1076–1093. 2019. View Article : Google Scholar :
|
40
|
Simon D, Derer A, Andes FT, Lezuo P, Bozec A, Schett G, Herrmann M and Harre U: Galectin-3 as a novel regulator of osteoblast-osteoclast interaction and bone homeostasis. Bone. 105:35–41. 2017. View Article : Google Scholar : PubMed/NCBI
|
41
|
Zhang J, Cai L, Tang L, Zhang X, Yang L, Zheng K, He A, Boccaccini AR, Wei J and Zhao J: Highly dispersed lithium doped mesoporous silica nanospheres regulating adhesion, proliferation, morphology, ALP activity and osteogenesis related gene expressions of BMSCs. Colloids Surf B Biointerfaces. 170:563–571. 2018. View Article : Google Scholar : PubMed/NCBI
|
42
|
Kang MR, Jo SA, Yoon YD, Park KH, Oh SJ, Yun J, Lee CW, Nam KH, Kim Y, Han SB, et al: Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB. Mar Drugs. 12:5643–5656. 2014. View Article : Google Scholar : PubMed/NCBI
|
43
|
Cai G, Aitken D, Laslett LL, Pelletier JP, Martel-Pelletier J, Hill C, March L, Wluka AE, Wang Y, Antony B, et al: Effect of intravenous zoledronic acid on tibiofemoral cartilage volume among patients with knee osteoarthritis with bone marrow lesions: A randomized clinical trial. JAMA. 323:1456–1466. 2020. View Article : Google Scholar : PubMed/NCBI
|
44
|
Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, Sone T, Taguchi A, Tanaka S, Ohashi M, et al: Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: Two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study). Osteoporosis Int. 28:389–398. 2017. View Article : Google Scholar
|
45
|
Wu GS, Lu JJ, Guo JJ, Huang MQ, Gan L, Chen XP and Wang YT: Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells. Pharmacol Rep. 65:453–459. 2013. View Article : Google Scholar : PubMed/NCBI
|
46
|
Crockett JC, Rogers MJ, Coxon FP, Hocking LJ and Helfrich MH: Bone remodelling at a glance. J Cell Sci. 124:991–998. 2011. View Article : Google Scholar : PubMed/NCBI
|
47
|
L Fvall H, Newbould H, Karsdal MA, Dziegiel MH, Richter J, Henriksen K and Thudium CS: Osteoclasts degrade bone and cartilage knee joint compartments through different resorption processes. Arthritis Res Ther. 20:672018. View Article : Google Scholar
|
48
|
Luo T, Liu H, Feng W, Liu D, Du J, Sun J, Wang W, Han X, Guo J, Amizuka N, et al: Adipocytes enhance expression of osteoclast adhesion-related molecules through the CXCL12/CXCR4 signalling pathway. Cell Prolif. 50:e123172017. View Article : Google Scholar
|
49
|
Tran MT, Okusha Y, Feng Y, Morimatsu M, Wei P, Sogawa C, Eguchi T, Kadowaki T, Sakai E, Okamura H, et al: The inhibitory role of Rab11b in osteoclastogenesis through triggering lysosome-induced degradation of c-Fms and RANK surface receptors. Int J Mol Sci. 21:93522020. View Article : Google Scholar :
|
50
|
Kimachi K, Kajiya H, Nakayama S, Ikebe T and Okabe K: Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis. Naunyn Schmiedebergs Arch Pharmacol. 383:297–308. 2011. View Article : Google Scholar : PubMed/NCBI
|
51
|
Liu W and Zhang X: Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review). Mol Med Rep. 11:3212–3218. 2015. View Article : Google Scholar : PubMed/NCBI
|
52
|
Zhao XL, Chen JJ, Si SY, Chen LF and Zhen W: T63 inhibits osteoclast differentiation through regulating MAPKs and Akt signaling pathways. Eur J Pharmacol. 834:30–35. 2018. View Article : Google Scholar : PubMed/NCBI
|
53
|
Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S and Inoue J: Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 20:1271–1280. 2001. View Article : Google Scholar : PubMed/NCBI
|
54
|
Fang C, He M, Li D and Xu Q: YTHDF2 mediates LPS-induced osteoclastogenesis and inflammatory response via the NF-κB and MAPK signaling pathways. Cell Signal. 85:1100602021. View Article : Google Scholar
|
55
|
Iijima H, Aoyama T, Tajino J, Ito A, Nagai M, Yamaguchi S, Zhang X, Kiyan W and Kuroki H: Subchondral plate porosity colocalizes with the point of mechanical load during ambulation in a rat knee model of post-traumatic osteoarthritis. Osteoarthritis Cartilage. 24:354–363. 2016. View Article : Google Scholar
|
56
|
Findlay DM and Kuliwaba JS: Bone-cartilage crosstalk: A conversation for understanding osteoarthritis. Bone Res. 4:160282016. View Article : Google Scholar : PubMed/NCBI
|
57
|
Sanchez C, Deberg MA, Piccardi N, Msika P, Reginster JY and Henrotin YE: Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by inter-leukin-6, -1beta and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthritis Cartilage. 13:979–987. 2005. View Article : Google Scholar : PubMed/NCBI
|
58
|
Priam S, Bougault C, Houard X, Gosset M, Salvat C, Berenbaum F and Jacques C: Identification of soluble 14-3-3ε as a novel subchondral bone mediator involved in cartilage degradation in osteoarthritis. Arthritis Rheum. 65:1831–1842. 2013. View Article : Google Scholar : PubMed/NCBI
|
59
|
Dou C, Zhang C, Kang F, Yang X, Jiang H, Bai Y, Xiang J, Xu J and Dong S: MiR-7b directly targets DC-STAMP causing suppression of NFATc1 and c-Fos signaling during osteoclast fusion and differentiation. Biochim Biophys Acta. 1839:1084–1096. 2014. View Article : Google Scholar : PubMed/NCBI
|